Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study.
diagnosis
hepatosplenic candidiasis
treatment
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
21
12
2021
accepted:
18
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Hepatosplenic candidiasis (HSC) used to be reported in patients with acute myeloid leukemia (AML) without antifungal prophylaxis. The aim was to describe the clinical features and outcomes of HSC over the last 13 years in a single French hematology center. All patients diagnosed with HSC between 2008 and 2020 were included in a single-center retrospective cohort study. Data were collected from patient charts, and HSC was classified according to the 2020 European Organisation for Research and Treatment of Cancer/Mycoses Study Group definitions. Sixty patients were included, with 18.3% proven, 3.3% probable, and 78.3% possible HSC according to the 2020 European Organization for Research and Treatment of Cancer Mycoses Study Group classification. Among them, 19 patients were treated for acute myeloid leukemia (AML), 21 for lymphomas, and 14 for acute lymphoblastic leukemia. HSC occurred in 13 patients after autologous stem cell transplantation for lymphoma. At HSC diagnosis, 13 patients were receiving antifungal prophylaxis. The epidemiology of HSC has changed in the last decade, with fewer cases occurring in the AML setting. A better identification of patients at risk could lead to specific prophylaxis and improved diagnosis.
Sections du résumé
Background
UNASSIGNED
Hepatosplenic candidiasis (HSC) used to be reported in patients with acute myeloid leukemia (AML) without antifungal prophylaxis. The aim was to describe the clinical features and outcomes of HSC over the last 13 years in a single French hematology center.
Methods
UNASSIGNED
All patients diagnosed with HSC between 2008 and 2020 were included in a single-center retrospective cohort study. Data were collected from patient charts, and HSC was classified according to the 2020 European Organisation for Research and Treatment of Cancer/Mycoses Study Group definitions.
Results
UNASSIGNED
Sixty patients were included, with 18.3% proven, 3.3% probable, and 78.3% possible HSC according to the 2020 European Organization for Research and Treatment of Cancer Mycoses Study Group classification. Among them, 19 patients were treated for acute myeloid leukemia (AML), 21 for lymphomas, and 14 for acute lymphoblastic leukemia. HSC occurred in 13 patients after autologous stem cell transplantation for lymphoma. At HSC diagnosis, 13 patients were receiving antifungal prophylaxis.
Conclusions
UNASSIGNED
The epidemiology of HSC has changed in the last decade, with fewer cases occurring in the AML setting. A better identification of patients at risk could lead to specific prophylaxis and improved diagnosis.
Identifiants
pubmed: 35355897
doi: 10.1093/ofid/ofac088
pii: ofac088
pmc: PMC8962726
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac088Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67
pubmed: 23137137
N Engl J Med. 2007 Jan 25;356(4):348-59
pubmed: 17251531
Clin Infect Dis. 1997 Mar;24(3):375-80
pubmed: 9114188
J Clin Microbiol. 2003 Oct;41(10):4551-8
pubmed: 14532181
Am J Med. 1991 Aug;91(2):142-50
pubmed: 1867240
Haematologica. 2002 May;87(5):535-41
pubmed: 12010669
J Antimicrob Chemother. 2012 Jun;67(6):1493-5
pubmed: 22374323
Clin Infect Dis. 2012 Mar 1;54(5):633-43
pubmed: 22198786
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
J Med Microbiol. 2002 May;51(5):433-442
pubmed: 11990496
Cancer Res. 1969 Feb;29(2):426-34
pubmed: 4975316
Br J Haematol. 1999 Sep;106(3):697-701
pubmed: 10468858
Clin Microbiol Infect. 2011 Mar;17(3):409-17
pubmed: 20636432
Z Gastroenterol. 2010 Jun;48(6):678-82
pubmed: 20517805
Ann Hematol. 1995 Feb;70(2):83-7
pubmed: 7880929
J Med Microbiol. 2009 May;58(Pt 5):606-615
pubmed: 19369522
Ann Hematol. 2014 Mar;93(3):493-8
pubmed: 23949318
Crit Care. 2010;14(6):R222
pubmed: 21143834
Infect Dis Clin North Am. 2000 Sep;14(3):721-39
pubmed: 10987117
Ann Intern Med. 1988 Jan;108(1):88-100
pubmed: 3276268
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Leuk Res. 2005 May;29(5):493-501
pubmed: 15755501
Eur J Haematol. 1996 Jan-Feb;56(1-2):82-7
pubmed: 8600000
Am J Med. 1991 Aug;91(2):137-41
pubmed: 1867239
Diagn Microbiol Infect Dis. 2005 Feb;51(2):95-101
pubmed: 15698714
Clin Microbiol Infect. 2012 Jun;18(6):E185-7
pubmed: 22458883
Intensive Care Med. 2019 Jun;45(6):789-805
pubmed: 30911804
J Fungi (Basel). 2018 Dec 17;4(4):
pubmed: 30562960
J Infect. 2018 May;76(5):483-488
pubmed: 29432826
Haematologica. 2006 Aug;91(8):1068-75
pubmed: 16885047
Mycoses. 2012 May;55(3):e74-84
pubmed: 22360318
J Infect Dis. 2020 May 11;221(11):1907-1916
pubmed: 31879764
Mycoses. 2021 Sep;64(9):1098-1110
pubmed: 33894072
Clin Infect Dis. 2008 Mar 1;46(5):696-702
pubmed: 18230039
Transplant Cell Ther. 2021 Aug;27(8):684.e1-684.e9
pubmed: 33964516
Medicine (Baltimore). 1998 Jul;77(4):246-54
pubmed: 9715729